SOUTH SAN FRANCISCO, Calif., April 4 /PRNewswire-FirstCall/ -- CoTherix, Inc. today announced that it has enrolled the first patient in the REVEAL Registry(TM), the first broadly defined registry designed to track and study the clinical course and medical management of pulmonary arterial hypertension (PAH). The REVEAL Registry is designed to provide physicians with real world data about PAH disease management.
The registry expects to enroll and follow for a minimum of five years consenting patients who have been diagnosed with World Health Organization (WHO) Group I PAH, regardless of their therapy. The registry will capture demographic data and clinical treatment patterns and factors associated with improved clinical outcomes. CoTherix's goal is for over 50 institutions to participate in the registry and to enroll approximately 3,000 PAH patients over a two-year period.
"We look forward to working closely with some of the top community and academic medical centers to uncover new insights into how PAH patients are diagnosed and treated," said James Pennington, M.D. Executive Vice President and Chief Medical Officer of CoTherix, Inc. "By building what we expect will be the largest reference set of data on PAH treatment to date, we hope to provide PAH caregivers with information that could help them more effectively treat PAH in the future."
About PAH
PAH affects an estimated 50,000 patients in the United States, with only about 15,000 diagnosed and under treatment. Its cause may be unknown, or result from other diseases that cause a restriction of blood flow to the lungs, including scleroderma, HIV and lupus. Symptoms of the disease include fatigue, shortness of breath on exertion, chest pain and dizziness. Left untreated, the median survival time following diagnosis may be as short as three years.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix's Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix, the CoTherix logo and REVEAL Registry are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding the REVEAL Registry, the number of institutions and patients expected to participate in the registry, the type of data collected and disseminated by the registry and the utility of that information, and the number of PAH patients in the United States. All forward-looking statements included in this press release are based upon information available as of the date hereof, and CoTherix does not assume any obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Events could differ materially from expectations. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors" section of CoTherix's most recent annual report on Form 10-K filed with the Securities and Exchange Commission.
CoTherix, Inc.CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
Web site: http://www.cotherix.com/
